Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health presented new modeling and real-world data at ACG 2026 showing its Shield blood test drove 99% screening adherence in rural South Carolina clinics and, per a lifetime simulation, averted more CRC deaths (12 vs. 6 for FIT and 9 for mt-sDNA) per 1,000 individuals. The modeling study found blood-based screening increased, not reduced, colonoscopy volume (679 vs. 113 and 326 per 1,000), countering a key payer concern that blood tests would siphon demand from colonoscopy.
Key figures
- Drug Name
- Shield
- Tests performed
- 200,000+
- Overall adherence rate
- over 90%
- Underserved adherence rate
- 99%
- Colonoscopies per 1000 blood based
- 679
- Crc deaths averted per 1000 blood based
- 12
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.